Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Penthrox – European Update

Feb 7, 2017Cathy WilsonNews

7 February 2017

ASX ANNOUNCEMENT

Penthrox: European update

Medical Developments International Limited (ASX: MVP) provides the following update on its Penthrox business in Europe.

United Kingdom and Ireland

In the United Kingdom and Ireland, Galen continue to make good progress in rolling out Penthrox.  34 Hospitals have approved and are now using Penthrox.  There are 11 major trauma center hospitals in the UK, four of which have approved and are using Penthrox.

For details relating to the full ASX release, please click on the following link: ASX Announcement – Penthrox European Update – 7 Feb 2017

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter